English
Earlier this year the American Medical Association (AMA) assigned a new, discreet Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT®) code for our revolutionary biomarker, Monocyte Distribution Width (MDW). This is an exciting development that brings great benefits to both healthcare professionals and patients.
“The recognition of MDW through a PLA Code exemplifies the trust and confidence placed in our capabilities and reaffirms our commitment to providing cutting-edge diagnostic solutions,” noted Shawn Schwartz, Associate Director, Market Access Health Economics & Policy at Beckman Coulter. “This significant milestone may help to transform patient outcomes through wider adoption of MDW within the medical community, which has the potential to decrease adverse sepsis outcomes.”
Unlike conditions and diseases such as heart failure and diabetes, there is no one test for sepsis, which is the yearly cause of 1 in 5 deaths.1 MDW, available on Beckman Coulter hematology analyzers, is the only regulatory-cleared hematological biomarker that helps to establish risk of severe infection and sepsis in adult patients in the ED. It is reported automatically as part of the complete blood count with differential (CBC-Diff) using the Early Sepsis Indicator (ESId) application, which enables automatic reporting with no workflow changes or need to order additional tests.
